<SEC-DOCUMENT>0001029142-25-000069.txt : 20250506
<SEC-HEADER>0001029142-25-000069.hdr.sgml : 20250506
<ACCEPTANCE-DATETIME>20250506160347
ACCESSION NUMBER:		0001029142-25-000069
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250506
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250506
DATE AS OF CHANGE:		20250506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		25917141

	BUSINESS ADDRESS:	
		STREET 1:		2100 POWELL STREET
		STREET 2:		SUITE 720
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2100 POWELL STREET
		STREET 2:		SUITE 720
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dvax-20250506.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:5c7d3e77-5111-4434-a6dc-25c26c5f238c,g:fbdfe23a-73e5-49b9-9742-fe19c965747a,d:16ee90ff796743eda96ef43a0919f03e-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dvax="http://www.dynavax.com/20250506" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dvax-20250506</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001029142</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dvax-20250506.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-06</xbrli:startDate><xbrli:endDate>2025-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-06</xbrli:startDate><xbrli:endDate>2025-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001029142</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dvax:PreferredSharePurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-06</xbrli:startDate><xbrli:endDate>2025-05-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i16ee90ff796743eda96ef43a0919f03e_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:1pt;margin-top:36pt;padding-right:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May&#160;6, 2025</ix:nonNumeric></span></div></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:14pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Dynavax Technologies Corporation</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-34207</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">33-0728374</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">(State or Other Jurisdiction</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:114%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">(IRS Employer</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:115%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">2100 Powell Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 720</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Emeryville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">94608</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:114%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">510</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">848-5100</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:28pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Trading</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-18">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.25pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-19">DVAX</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.25pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-21">Preferred Share Purchase Rights</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-3" name="dei:NoTradingSymbolFlag" format="ixt:fixed-true" id="f-22">N/A</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-23">Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:36pt;padding-right:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i16ee90ff796743eda96ef43a0919f03e_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6, 2025, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the first quarter ended March&#160;31, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. </span></div><div style="margin-top:12pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div id="i16ee90ff796743eda96ef43a0919f03e_10"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits. The following exhibit is furnished herewith: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.840%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="dvax-exx991xearningspressr.htm">Press release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="dvax-exx991xearningspressr.htm">May</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="dvax-exx991xearningspressr.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="dvax-exx991xearningspressr.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="dvax-exx991xearningspressr.htm">, 2025 titled "</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="dvax-exx991xearningspressr.htm">Dynavax Reports First Quarter 2025 Financial Results </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="dvax-exx991xearningspressr.htm">and Announces New Pipeline Programs</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="dvax-exx991xearningspressr.htm">."</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i16ee90ff796743eda96ef43a0919f03e_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dynavax Technologies Corporation </span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;6, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Kelly MacDonald </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Kelly MacDonald</span></div><div style="margin-top:0.72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senior Vice President, CFO</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dvax-exx991xearningspressr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i1d68c9bb43a7444bba44746196e5a3d2_1"></div><div style="min-height:45pt;width:100%"><div><img alt="a1a.jpg" src="a1a.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs</font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:39.53pt">Record HEPLISAV-B&#174; first quarter net product revenue of $65 million, representing 36% year-over-year growth</font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:39.53pt">Top-line results in Part 1 of Phase 1&#47;2 shingles vaccine trial expected in Q3 2025</font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:39.53pt">New pandemic influenza adjuvant program and Lyme disease vaccine programs planned to enter clinical development in 2025 and 2027, respectively </font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:39.53pt">Conference call today at 4&#58;30 p.m. ET&#47;1&#58;30 p.m. PT</font></div><div style="padding-left:58.5pt;text-indent:-27pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">EMERYVILLE, CA &#8211; May 6, 2025 &#8211; Dynavax Technologies Corporation (Nasdaq&#58; DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We started 2025 off strong, executing across our </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">strategic growth initiatives, including delivering our highest first quarter </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">net product revenue for HEPLISAV-B to date, putting us on track to achieve the top half of our full year guidance range. We are also excited to advance our pipeline leveraging our leading vaccine adjuvant technology, CpG 1018, with key clinical trial milestones this year for our shingles and plague vaccine programs, while further broadening our pipeline with new programs in pandemic influenza and Lyme disease,&#34; said Ryan Spencer, Chief Executive Officer of Dynavax. &#8220;We continue to focus on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">maintaining a disciplined approach to capital allocation, including executing over 80% of our share repurchase program to date, while evaluating external opportunities that leverage our infrastructure and capabilities to generate additional long-term growth for our shareholders and other stakeholders.&#34;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">BUSINESS UPDATES</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">HEPLISAV-B&#174; &#91;Hepatitis B Vaccine (Recombinant), Adjuvanted&#93;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">HEPLISAV-B vaccine is the first and only adult hepatitis B vaccine approved in the U.S., the European Union and the United Kingdom that enables series completion with only two doses in one month. In the U.S., hepatitis B vaccination is recommended for adults aged 19 to 59, and for adults aged 60 and older with risk factors, while adults aged 60 and older without known risk factors may also be vaccinated.</font></div><div style="margin-top:6pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:39.53pt">HEPLISAV-B achieved net product revenue of $65.0 million for the first quarter of 2025, an increase of 36% compared to $47.8 million for the first quarter of 2024.</font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:39.53pt">HEPLISAV-B total estimated market share in the U.S. increased to approximately 43%, compared to approximately 41% for the first quarter 2024.</font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:39.53pt">Dynavax continues to expect the hepatitis B adult vaccine market in the U.S. to expand to a peak of over $900 million in annual sales by 2030, with HEPLISAV-B expected to achieve at least 60% total market share. Additionally, Dynavax believes the HEPLISAV-B U.S. market opportunity will remain substantial beyond 2030 due to the ongoing penetration of the unvaccinated eligible adult population, observed revaccination practices by healthcare providers, and continued gains in market share.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Clinical and Preclinical Pipeline</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Dynavax is advancing a pipeline of differentiated product candidates that leverage its CpG 1018&#174; adjuvant, which has demonstrated its ability to enhance the immune response with a favorable tolerability profile in a wide range of clinical trials and real-world commercial use.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><img alt="a1a.jpg" src="a1a.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Shingles Vaccine Program&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Z-1018</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">is an investigational vaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">candidate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">being developed for the prevention of shingles in adults aged 50 years and older.</font></div><div style="margin-top:6pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:39.53pt">Dynavax is currently conducting Part 1 of a Phase 1&#47;2 clinical trial, a randomized, active-controlled, dose escalation, multicenter study, to evaluate the safety, tolerability, and immunogenicity of Z-1018 compared to Shingrix&#174; in 441 healthy adults aged 50 to 69. </font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:39.53pt">In the fourth quarter of 2024, Dynavax completed enrollment in Part 1, and anticipates reporting top-line immunogenicity and safety data in the third quarter of 2025.</font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:39.53pt">Dynavax plans to advance the selected vaccine formulation and regimen from Part 1 into Part 2 of the Phase 1&#47;2 study in adults over age 70 years to generate clinical proof-of-concept in this key population, with key endpoints including tolerability and immunogenicity comparisons to Shingrix, ahead of advancement into a pivotal trial.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Plague Vaccine Program&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Dynavax is developing a plague (rF1V) vaccine candidate adjuvanted with CpG 1018&#174; in collaboration with, and fully funded by, the U.S. Department of Defense (DoD).</font></div><div style="margin-top:6pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:39.53pt">In the fourth quarter of 2024, Dynavax and the DoD executed a new agreement for approximately $30 million through the first half of 2027 to support additional clinical and manufacturing activities, including a Phase 2 clinical trial expected to initiate in the third quarter of 2025.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pandemic Influenza Adjuvant Program&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Dynavax is evaluating CpG 1018 in an adjuvanted H5N1 influenza vaccine as a proof-of-concept for its potential use with pandemic influenza vaccines.</font></div><div style="margin-top:6pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:41.15pt">Pandemic influenza remains one of the most persistent and unpredictable global health threats. Vaccine adjuvants play an essential role in pandemic preparedness, mostly due to their dose sparing capability, yet despite their critical importance, the global supply of proven adjuvants remains limited. </font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:39.53pt">Leveraging its expertise and capabilities as a global supplier of CpG 1018 adjuvant for the development of multiple COVID-19 vaccines, Dynavax intends to generate clinical proof-of-concept for CpG 1018-adjuvanted pandemic influenza vaccines to support the potential commercial supply of vaccine adjuvant needed for global pandemic preparedness and response efforts. </font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:39.53pt">In the second quarter of 2025, Dynavax expects to initiate a randomized, active-controlled Phase 1&#47;2 study to evaluate the safety and immunogenicity of an investigational H5N1 influenza vaccine adjuvanted with CpG 1018.</font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:39.53pt">Part 1 of the Phase 1&#47;2 trial is expected to enroll approximately 98 participants aged 18 to 49 years to receive either single-dose or two-dose formulations of the investigational vaccine, with the intention to select the optimal formulations of CpG 1018 adjuvant for Part 2 of the Phase 1&#47;2 trial.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lyme Disease Vaccine Program&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Dynavax is developing an investigational</font><font style="background-color:#f2f2f2;color:#828282;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">multivalent protein subunit vaccine candidate adjuvanted with CpG 1018 for the prevention of Lyme disease, a bacterial infection that is the most common vector-borne illness in the Northern Hemisphere.</font></div><div style="margin-top:6pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:41.15pt">There are currently no approved human vaccines for Lyme disease and current vaccine candidates in clinical development require three-dose primary series and annual boosters. Dynavax believes its investigational Lyme disease vaccine adjuvanted with CpG 1018, which has a demonstrated ability to amplify immune responses and improve durability of protection, has the potential for a differentiated and best-in-class vaccine profile. </font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:39.53pt">Dynavax&#8217;s Lyme disease vaccine candidate has progressed into Investigational New Drug (IND)-enabling studies, with plans to initiate clinical development in 2027.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><img alt="a1a.jpg" src="a1a.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HEPLISAV-B for Adults on Hemodialysis&#58;</font></div><div style="margin-top:6pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:39.53pt">Dynavax plans to conduct an observational retrospective cohort study to support its sBLA filing for a HEPLISAV-B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> vaccine regimen for adults on hemodialysis. In the first quarter of 2025, Dynavax received feedback from the U.S. Food and Drug Administration (FDA) that its proposed patient database may be acceptable for the observational retrospective cohort study, and Dynavax is engaging with the FDA to finalize the study protocol.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">FIRST QUARTER 2025 FINANCIAL HIGHLIGHTS</font></div><div style="margin-top:6pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:39.53pt">Total revenues</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> were $68.2 million for the first quarter of 2025, a 34% increase compared to $50.8 million for the first quarter of 2024. </font></div><div style="margin-top:3pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:39.53pt">HEPLISAV-B net product revenue </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">was $65.0 million for the first quarter of 2025, a 36% increase compared to $47.8 million for the first quarter of 2024.</font></div><div style="margin-top:3pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:39.53pt">Cost of sales - product</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">for HEPLISAV-B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> were $13.8 million for the first quarter of 2025, compared to $11.0 million for the first quarter of 2024. </font></div><div style="margin-top:3pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:39.53pt">Research and development expenses (R&#38;D)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> were $19.4 million for the first quarter of 2025, compared to $13.5 million for the first quarter of 2024.</font></div><div style="margin-top:3pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:39.53pt">Selling, general, and administrative expenses (SG&#38;A)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> were $47.7 million for the first quarter of 2025, compared to $44.1 million for the first quarter of 2024.</font></div><div style="margin-top:3pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:39.53pt">Bad debt expense </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">During the first quarter of 2025, Dynavax recorded an allowance for doubtful accounts of $11.0 million relating to the adjuvant commercial supply agreement with Clover Biopharmaceuticals. This bad debt expense reflects an assessed heightened credit risk associated with Clover, primarily due to Gavi, the Vaccine Alliance's termination of its advanced purchase agreement, coupled with Clover&#8217;s recently reported write-down of its CpG 1018 adjuvant and liquidity position as of December 31, 2024.</font></div><div style="margin-top:3pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:39.53pt">GAAP net loss</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> was $96.1 million, or a net loss of $0.77 per share (basic and diluted) for the first quarter of 2025, compared to GAAP net loss of $8.7 million, or a net loss of $0.07 per share (basic and diluted) for the first quarter of 2024. The net loss in the first quarter of 2025 was primarily due to a loss on the extinguishment of debt relating to the convertible debt refinancing in March 2025. </font></div><div style="margin-top:3pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:39.53pt">Adjusted EBITDA*</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> was negative $4.4 million for the first quarter of 2025, compared to negative $6.8 million for the first quarter of 2024.</font></div><div style="margin-top:3pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:39.53pt">Cash, cash equivalents and marketable securities</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> were $661.3 million as of March 31, 2025, compared to $713.8 million as of December 31, 2024. </font></div><div style="margin-top:3pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:39.53pt">Convertible debt refinancing&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In March 2025, Dynavax refinanced a majority of its outstanding convertible senior notes, which extended the maturity date of most of its existing debt, lowered its overall cost of capital through improved terms, and reduced basic and diluted shares outstanding. </font></div><div style="margin-top:3pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:39.53pt">Share repurchase program&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In November 2024, Dynavax announced a $200.0 million share repurchase program authorized by its Board of Directors, including $100.0 million repurchased through an accelerated share repurchase program, which was completed in the first quarter of 2025. As of May 5, 2025, Dynavax has repurchased $172.0 million worth of common stock under the $200.0 million share repurchase program and anticipates completing the remaining repurchases by the end of 2025.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">FULL YEAR 2025 FINANCIAL GUIDANCE</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Dynavax is reaffirming its full year 2025 financial guidance, based on its current operating plan&#58; </font></div><div style="margin-top:6pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:39.53pt">HEPLISAV-B net product revenue</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> is expected in the range of $305 to $325 million.</font></div><div style="margin-top:3pt;padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:39.53pt">Adjusted EBITDA* </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">is expected to be at least $75 million.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">* Non-GAAP financial measure. Please refer to the &#8220;Non-GAAP Financial Measures&#8221; section for details regarding this measure.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><img alt="a1a.jpg" src="a1a.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast Information</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Dynavax will host a conference call and live audio webcast on Tuesday, May&#160;6, 2025, at 4&#58;30 p.m. ET&#47;1&#58;30 p.m. PT. The live audio webcast may be accessed through the &#34;Events &#38; Presentations&#34; page on the &#34;Investors&#34; section of Dynavax's website at https&#58;&#47;&#47;investors.dynavax.com&#47;events-presentations. A replay of the webcast will be available for 30 days following the live event.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To dial into the call, participants will need to register for the call using the caller registration link at https&#58;&#47;&#47;investors.dynavax.com&#47;events-presentations and under the &#8220;Upcoming Events&#8221; section, click on &#34;Listen to webcast&#34;. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHAT IS HEPLISAV-B&#63;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">HEPLISAV-B is a shot given to adults 18 years of age and older to help prevent infection caused by the hepatitis B virus. HEPLISAV-B is usually given in the arm muscle. HEPLISAV-B is given in 2 doses, 1 month apart, by a healthcare provider. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">IMPORTANT SAFETY INFORMATION</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">There are no adequate and well-controlled studies of HEPLISAV-B in pregnant individuals. Available data, primarily in individuals who received one dose of HEPLISAV-B in the 28 days prior to or during pregnancy, do not suggest an increased risk of major birth defects and miscarriage. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">It is not known whether HEPLISAV-B is excreted in human milk.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Data are not available to assess the effects of HEPLISAV-B on the breastfed infant or on milk production&#47;excretion.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Vaccination with HEPLISAV-B may not result in protection of all vaccine recipients.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Talk to your healthcare provider to determine if HEPLISAV-B is right for you.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For full U.S. Prescribing Information for HEPLISAV-B, please visit the following website at https&#58;&#47;&#47;www.heplisavbhcp.com, and click the &#8220;Prescribing Information&#8221; link in the &#8220;Important Safety Information&#8221; section.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Dynavax</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. Dynavax has two commercial products, HEPLISAV-B&#174; vaccine &#91;Hepatitis B Vaccine (Recombinant), Adjuvanted&#93;, which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><img alt="a1a.jpg" src="a1a.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">hepatitis B virus in adults 18 years of age and older, and CpG 1018&#174; adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about Dynavax's marketed products and development pipeline, visit www.dynavax.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Non-GAAP Financial Measures</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">To supplement financial results presented on a GAAP basis, Dynavax has included information about adjusted EBITDA, a non-GAAP financial measure. Dynavax believes the presentation of this non-GAAP financial measure, when viewed with its results under GAAP and the accompanying reconciliation, provide analysts, investors and other third parties with insights into how Dynavax evaluates normal operational activities, including its ability to generate cash from operations, on a comparable year-over-year basis and manage its budgeting and forecasting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In quarterly and annual reports, earnings press releases and conference calls, Dynavax may discuss Adjusted EBITDA to supplement its consolidated financial statements presented on a GAAP basis. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Adjusted EBITDA</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in Dynavax's business but do not represent ongoing operations, including loss on debt extinguishment and proxy contest costs. Adjusted EBITDA, as used by Dynavax, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">There are several limitations related to the use of adjusted EBITDA rather than net income or loss, which is the nearest GAAP equivalent, such as&#58;</font></div><div><font><br></font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:39.53pt">adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA&#59;</font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:39.53pt">adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs&#59;</font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:39.53pt">adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes&#59;</font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:39.53pt">adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments&#59;</font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:39.53pt">Dynavax excludes stock-based compensation expense from adjusted EBITDA although&#58; (i) it has been, and will continue to be for the foreseeable future, a significant recurring expense for its business and an important part of its compensation strategy&#59; and (ii) if Dynavax did not pay out a portion of its compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect its cash position&#59;</font></div><div style="padding-left:94.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:39.53pt">From time to time, Dynavax may exclude other expenses, that are episodic in nature and do not directly correlate to the cost of operating its business on an ongoing basis, such as loss on debt extinguishment and proxy contest costs.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Reconciliation of each historical non-GAAP financial measure to Adjusted EBITDA can be found in the table accompanying this press release. Dynavax has not provided a reconciliation of its full-year 2025 guidance for Adjusted EBITDA to the most directly comparable forward-looking GAAP measures because it is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, income tax expense or provision for income taxes. These items are uncertain and depend on various factors that are outside of Dynavax&#8217;s control or cannot be reasonably predicted. While Dynavax is unable to address the probable significance of these items, they could have a material impact on GAAP net income for the guidance period. A reconciliation of Adjusted EBITDA would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><img alt="a1a.jpg" src="a1a.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Forward-Looking Statements</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains &#34;forward-looking&#34; statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements. Forward-looking statements can generally be identified by the use of words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;would&#8221; and similar expressions, or the negatives thereof, or they may use future dates. Forward-looking statements made in this document include statements regarding Dynavax's expected financial results for the quarter ended March 31, 2025, expectations regarding its future growth and long term performance, extent and timing of market growth and market share beyond 2030, the timing of IND filings, initiation and completion of clinical studies, expected timing for data readouts, and interaction with regulators. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Dynavax's business, including, the risk that market size or actual demand for its products may differ from its expectations, risks relating to its ability to commercialize and supply HEPLISAV-B, risks related to the timing of completion and results of current clinical studies, risks related to the development and preclinical and clinical testing of vaccines containing CpG 1018 adjuvant, as well as other risks detailed in the &#34;Risk Factors&#34; section of its Quarterly Report on Form 10-Q for the three months ended March&#160;31, 2025 and periodic filings made thereafter, as well as discussions of potential risks, uncertainties and other important factors in its other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date hereof, are qualified in their entirety by this cautionary statement and Dynavax undertakes no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in its current periodic reports with the SEC.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Reference herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not constitute or imply its endorsement, recommendation, or favoring by the U.S. Government and shall not be used for advertising or product endorsement purposes.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For Investors&#47;Media&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Paul Cox</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">pcox&#64;dynavax.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">510-665-0499</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nicole Arndt</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">narndt&#64;dynavax.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">510-665-7264</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1d68c9bb43a7444bba44746196e5a3d2_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><img alt="a1a.jpg" src="a1a.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DYNAVAX TECHNOLOGIES CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">2025</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:2.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Product revenue, net</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">64,959&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">47,845&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Other revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">3,205&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">2,945&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">68,164</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">50,790</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Cost of sales - product</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">13,769&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">10,966&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">19,377&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">13,528&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">47,678&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">44,065&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Bad debt expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">10,970&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">91,794</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">68,559</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Loss from operations</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">(23,630)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">(17,769)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Other income (expense)&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">7,739&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">9,468&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Interest expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">(1,692)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">(1,695)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Sublease income (expense) (Note 5)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">2,226&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">(1,602)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Loss on debt extinguishment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">(82,095)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Other (loss) income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">(423)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">101&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Net loss before income taxes</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">(97,875)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">(11,497)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Benefit from income taxes</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">1,776&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">2,776&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Net loss</font></div></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">(96,099)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">(8,721)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Net loss per share attributable to common stockholders</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">(0.77)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">(0.07)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">(0.77)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">(0.07)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Weighted-average shares used in computing net loss per share attributable to common stockholders&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Basic</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">124,871</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">130,200</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Diluted</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">124,871</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">130,200</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1d68c9bb43a7444bba44746196e5a3d2_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><img alt="a1a.jpg" src="a1a.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DYNAVAX TECHNOLOGIES CORPORATION </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SELECTED BALANCE SHEET DATA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">March 31,<br>2025</font></td><td colspan="3" style="padding:0 1pt 0 3.77pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 3.77pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt 0 3.77pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 3.77pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">661,336</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 3.77pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">713,834</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Inventories</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,403&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 3.77pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,054&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Other current assets</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,231&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,053&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Total current assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">815,970</font></td><td colspan="3" style="background-color:#cceeff;padding:0 3.77pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">848,941</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Total non-current assets</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,958&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,315&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">945,928</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 3.77pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">986,256</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 3.77pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt 0 3.77pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #ffffff;padding:0 1pt 0 3.77pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt 0 3.77pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Liabilities and stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 3.77pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 3.77pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 3.77pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Total current liabilities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,379&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,634&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Total long-term liabilities</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,608&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,823&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Stockholders&#8217; equity</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,941&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,799&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">945,928</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #ffffff;padding:0 1pt 0 3.77pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">$</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">986,256</font></td></tr></table></div><div style="margin-top:24pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1d68c9bb43a7444bba44746196e5a3d2_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><img alt="a1a.jpg" src="a1a.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DYNAVAX TECHNOLOGIES CORPORATION </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Three Months Ended</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP net loss</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(96,099)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(8,721)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Depreciation &#38; amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">374&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">375&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(7,739)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9,468)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,692&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,695&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Benefit from income taxes</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,776)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2,776)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Total adjustments</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(7,449)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(10,174)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">EBITDA</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(103,548)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(18,895)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Stock-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13,449&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12,144&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Loss on debt extinguishment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">82,095&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Proxy contest costs </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,648&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Adjusted EBITDA</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(4,356)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(6,751)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>dvax-20250506.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:5c7d3e77-5111-4434-a6dc-25c26c5f238c,g:fbdfe23a-73e5-49b9-9742-fe19c965747a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dvax="http://www.dynavax.com/20250506" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.dynavax.com/20250506">
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dvax-20250506_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dvax-20250506_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dvax-20250506_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.dynavax.com/role/DocumentAndEntityInformation">
        <link:definition>0000001 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="dvax_PreferredSharePurchaseRightsMember" abstract="true" name="PreferredSharePurchaseRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>dvax-20250506_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:5c7d3e77-5111-4434-a6dc-25c26c5f238c,g:fbdfe23a-73e5-49b9-9742-fe19c965747a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.dynavax.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="dvax-20250506.xsd#DocumentAndEntityInformation"/>
  <link:definitionLink xlink:role="http://www.dynavax.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_77834d7f-9ee3-40ce-bb58-26ca9c4bedec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_DocumentInformationTable_77834d7f-9ee3-40ce-bb58-26ca9c4bedec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d0827943-1bf8-4457-b6a8-d503d8ef06ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_77834d7f-9ee3-40ce-bb58-26ca9c4bedec" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d0827943-1bf8-4457-b6a8-d503d8ef06ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d0827943-1bf8-4457-b6a8-d503d8ef06ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d0827943-1bf8-4457-b6a8-d503d8ef06ac" xlink:to="loc_us-gaap_ClassOfStockDomain_d0827943-1bf8-4457-b6a8-d503d8ef06ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5aeb803f-4050-4380-8b1f-f5762904d5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d0827943-1bf8-4457-b6a8-d503d8ef06ac" xlink:to="loc_us-gaap_ClassOfStockDomain_5aeb803f-4050-4380-8b1f-f5762904d5f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c799dca4-c9b7-4ce6-9b1c-90cda4f86e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5aeb803f-4050-4380-8b1f-f5762904d5f0" xlink:to="loc_us-gaap_CommonStockMember_c799dca4-c9b7-4ce6-9b1c-90cda4f86e7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dvax_PreferredSharePurchaseRightsMember_b7624844-85c8-46c5-af1d-d9044299b2fc" xlink:href="dvax-20250506.xsd#dvax_PreferredSharePurchaseRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5aeb803f-4050-4380-8b1f-f5762904d5f0" xlink:to="loc_dvax_PreferredSharePurchaseRightsMember_b7624844-85c8-46c5-af1d-d9044299b2fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_62d7b219-c7d8-4047-b3c4-38b06790a100" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_DocumentType_62d7b219-c7d8-4047-b3c4-38b06790a100" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7411b01d-b7be-43b9-85e0-a8c44f13b8e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_DocumentPeriodEndDate_7411b01d-b7be-43b9-85e0-a8c44f13b8e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2b76240c-c1c0-4028-b982-0a9e472de888" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityRegistrantName_2b76240c-c1c0-4028-b982-0a9e472de888" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5734e6f4-2bca-4132-bcf4-097d5a8382cd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5734e6f4-2bca-4132-bcf4-097d5a8382cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_70245348-cca8-44e1-83ea-7d1efaee2fa0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityFileNumber_70245348-cca8-44e1-83ea-7d1efaee2fa0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_81f8ade0-aab3-43b4-98a2-80328357064c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityTaxIdentificationNumber_81f8ade0-aab3-43b4-98a2-80328357064c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6666b413-98b3-48d4-b9b0-a9e4a0bb2f0e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityAddressAddressLine1_6666b413-98b3-48d4-b9b0-a9e4a0bb2f0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_fdf8ecda-cf34-4f15-bfdc-da950d756b5c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityAddressAddressLine2_fdf8ecda-cf34-4f15-bfdc-da950d756b5c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_26ea8345-c567-465d-8daf-4325f107c6a7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityAddressCityOrTown_26ea8345-c567-465d-8daf-4325f107c6a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b731e15b-f732-4154-9f8a-61e4022f8a29" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityAddressStateOrProvince_b731e15b-f732-4154-9f8a-61e4022f8a29" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f83748f8-cae5-4823-a765-dd9b82cafc46" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityAddressPostalZipCode_f83748f8-cae5-4823-a765-dd9b82cafc46" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_53e266fc-5e7c-4337-9ee0-f47ca9e6e56f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_CityAreaCode_53e266fc-5e7c-4337-9ee0-f47ca9e6e56f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a03496e5-5c21-4223-bd9d-65fe79c09f29" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_LocalPhoneNumber_a03496e5-5c21-4223-bd9d-65fe79c09f29" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_83b02433-6ca0-4005-b47d-a3ce0c61881f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_WrittenCommunications_83b02433-6ca0-4005-b47d-a3ce0c61881f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_fc73c21c-84a7-4107-9e5a-42ba3541e64d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_SolicitingMaterial_fc73c21c-84a7-4107-9e5a-42ba3541e64d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b40b6476-0ab3-4320-890e-c64c7472a5ff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_PreCommencementTenderOffer_b40b6476-0ab3-4320-890e-c64c7472a5ff" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_75cc5fbf-5e67-4a11-b035-237be63c2e2c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_75cc5fbf-5e67-4a11-b035-237be63c2e2c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_76c6fa3c-47fb-4991-b2b7-7c2fdfe72362" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_Security12bTitle_76c6fa3c-47fb-4991-b2b7-7c2fdfe72362" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4b436330-604f-4036-9df5-7ee1de7b472c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_TradingSymbol_4b436330-604f-4036-9df5-7ee1de7b472c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_3155bac9-a016-4ee1-aca1-465c53c3de76" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_NoTradingSymbolFlag_3155bac9-a016-4ee1-aca1-465c53c3de76" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_204ef8ad-4cf4-4667-9e4e-9e7662b96f50" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_SecurityExchangeName_204ef8ad-4cf4-4667-9e4e-9e7662b96f50" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4143d10e-3011-42ff-a61a-799fb80a7bf8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityEmergingGrowthCompany_4143d10e-3011-42ff-a61a-799fb80a7bf8" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_74fd64b1-9d66-4add-970b-8b26d907eec3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityCentralIndexKey_74fd64b1-9d66-4add-970b-8b26d907eec3" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_74011290-b1b1-4761-894a-5559c1d9eb7f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_AmendmentFlag_74011290-b1b1-4761-894a-5559c1d9eb7f" xlink:type="arc" order="23"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>dvax-20250506_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:5c7d3e77-5111-4434-a6dc-25c26c5f238c,g:fbdfe23a-73e5-49b9-9742-fe19c965747a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ClassOfStockDomain_35fa538a-bffc-44d4-b3c3-9b11f9061bf9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_432e551b-63a2-4fff-8c09-1525486a0860_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1933e8dc-ccbd-4a1f-9a62-383362f2c6a0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_005b8760-e516-48fc-b785-4cfc5daedf8a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_NoTradingSymbolFlag_33e1d289-855f-47b5-8c77-7128a3c22206_terseLabel_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:label id="lab_dei_NoTradingSymbolFlag_label_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NoTradingSymbolFlag" xlink:to="lab_dei_NoTradingSymbolFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_98ebf7be-15b4-4688-b6d4-349b7089d639_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_38559378-6d78-4967-a536-c0fc66068228_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_32075204-b2e7-4147-b102-641c512fe0da_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_256832b6-6da7-4854-baba-d1a7118b09c6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fd6987f4-5d1c-486e-a3b0-32a298fa877a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b308d3fb-7b73-4f6d-ab3e-c284c3fbd9f9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9cc1d244-cf89-4f77-90d9-5cc1b513780b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_db806ee3-bc73-4673-aa63-87db208210bb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_db6edbfb-cea9-417a-9866-60cd93528391_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_180acb6e-2296-40aa-ac7f-3a640dda6fed_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_811c37a7-c6b2-47a6-8610-fc8dcc2a9a49_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_22dcaf43-f3eb-41b0-a6a7-e505d71c131a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6f8299ba-f94f-4ff9-8c0d-a763058f8afd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b51b4c42-e0ca-4eb4-94a8-00db274d118c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_08cd0947-8449-4278-b0ff-9ce18bcb7d8d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b5ad330b-38f3-4533-bcdf-f5c07fe4646f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_c7ab0eef-96aa-460c-aa9a-16e26abfa52e_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_f4ed08cf-0700-47d0-be39-d27f448cc781_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1b032407-d259-4bd5-897a-b81c0900e80f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_0acf975c-5929-44d4-b992-b1539d059ba1_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_d62c645c-97b8-4bf7-9a2b-736c647ff3fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1354c6dd-4daa-49e8-b5f4-df4dbd5972c8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e867fe8c-20f5-4d9a-a378-72a7ed24cafc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dvax_PreferredSharePurchaseRightsMember_e91fcf40-9844-435c-bf7d-0abd74543308_terseLabel_en-US" xlink:label="lab_dvax_PreferredSharePurchaseRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Share Purchase Rights</link:label>
    <link:label id="lab_dvax_PreferredSharePurchaseRightsMember_label_en-US" xlink:label="lab_dvax_PreferredSharePurchaseRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Share Purchase Rights [Member]</link:label>
    <link:label id="lab_dvax_PreferredSharePurchaseRightsMember_documentation_en-US" xlink:label="lab_dvax_PreferredSharePurchaseRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Share Purchase Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dvax_PreferredSharePurchaseRightsMember" xlink:href="dvax-20250506.xsd#dvax_PreferredSharePurchaseRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dvax_PreferredSharePurchaseRightsMember" xlink:to="lab_dvax_PreferredSharePurchaseRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_38452bf0-d095-4bc2-a175-34ea5fe0e184_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3cc36362-33f1-4ebb-ae86-ed3032f8d1c5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>dvax-20250506_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:5c7d3e77-5111-4434-a6dc-25c26c5f238c,g:fbdfe23a-73e5-49b9-9742-fe19c965747a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.dynavax.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="dvax-20250506.xsd#DocumentAndEntityInformation"/>
  <link:presentationLink xlink:role="http://www.dynavax.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b1af4cf8-a680-4d15-ad24-10bd3a4483a3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_77834d7f-9ee3-40ce-bb58-26ca9c4bedec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1af4cf8-a680-4d15-ad24-10bd3a4483a3" xlink:to="loc_dei_DocumentInformationTable_77834d7f-9ee3-40ce-bb58-26ca9c4bedec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d0827943-1bf8-4457-b6a8-d503d8ef06ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_77834d7f-9ee3-40ce-bb58-26ca9c4bedec" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d0827943-1bf8-4457-b6a8-d503d8ef06ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5aeb803f-4050-4380-8b1f-f5762904d5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d0827943-1bf8-4457-b6a8-d503d8ef06ac" xlink:to="loc_us-gaap_ClassOfStockDomain_5aeb803f-4050-4380-8b1f-f5762904d5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c799dca4-c9b7-4ce6-9b1c-90cda4f86e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5aeb803f-4050-4380-8b1f-f5762904d5f0" xlink:to="loc_us-gaap_CommonStockMember_c799dca4-c9b7-4ce6-9b1c-90cda4f86e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dvax_PreferredSharePurchaseRightsMember_b7624844-85c8-46c5-af1d-d9044299b2fc" xlink:href="dvax-20250506.xsd#dvax_PreferredSharePurchaseRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5aeb803f-4050-4380-8b1f-f5762904d5f0" xlink:to="loc_dvax_PreferredSharePurchaseRightsMember_b7624844-85c8-46c5-af1d-d9044299b2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_77834d7f-9ee3-40ce-bb58-26ca9c4bedec" xlink:to="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_62d7b219-c7d8-4047-b3c4-38b06790a100" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_DocumentType_62d7b219-c7d8-4047-b3c4-38b06790a100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7411b01d-b7be-43b9-85e0-a8c44f13b8e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_DocumentPeriodEndDate_7411b01d-b7be-43b9-85e0-a8c44f13b8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2b76240c-c1c0-4028-b982-0a9e472de888" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityRegistrantName_2b76240c-c1c0-4028-b982-0a9e472de888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5734e6f4-2bca-4132-bcf4-097d5a8382cd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5734e6f4-2bca-4132-bcf4-097d5a8382cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_70245348-cca8-44e1-83ea-7d1efaee2fa0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityFileNumber_70245348-cca8-44e1-83ea-7d1efaee2fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_81f8ade0-aab3-43b4-98a2-80328357064c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityTaxIdentificationNumber_81f8ade0-aab3-43b4-98a2-80328357064c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6666b413-98b3-48d4-b9b0-a9e4a0bb2f0e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityAddressAddressLine1_6666b413-98b3-48d4-b9b0-a9e4a0bb2f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_fdf8ecda-cf34-4f15-bfdc-da950d756b5c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityAddressAddressLine2_fdf8ecda-cf34-4f15-bfdc-da950d756b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_26ea8345-c567-465d-8daf-4325f107c6a7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityAddressCityOrTown_26ea8345-c567-465d-8daf-4325f107c6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b731e15b-f732-4154-9f8a-61e4022f8a29" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityAddressStateOrProvince_b731e15b-f732-4154-9f8a-61e4022f8a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f83748f8-cae5-4823-a765-dd9b82cafc46" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityAddressPostalZipCode_f83748f8-cae5-4823-a765-dd9b82cafc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_53e266fc-5e7c-4337-9ee0-f47ca9e6e56f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_CityAreaCode_53e266fc-5e7c-4337-9ee0-f47ca9e6e56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a03496e5-5c21-4223-bd9d-65fe79c09f29" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_LocalPhoneNumber_a03496e5-5c21-4223-bd9d-65fe79c09f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_83b02433-6ca0-4005-b47d-a3ce0c61881f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_WrittenCommunications_83b02433-6ca0-4005-b47d-a3ce0c61881f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_fc73c21c-84a7-4107-9e5a-42ba3541e64d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_SolicitingMaterial_fc73c21c-84a7-4107-9e5a-42ba3541e64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b40b6476-0ab3-4320-890e-c64c7472a5ff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_PreCommencementTenderOffer_b40b6476-0ab3-4320-890e-c64c7472a5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_75cc5fbf-5e67-4a11-b035-237be63c2e2c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_75cc5fbf-5e67-4a11-b035-237be63c2e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_76c6fa3c-47fb-4991-b2b7-7c2fdfe72362" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_Security12bTitle_76c6fa3c-47fb-4991-b2b7-7c2fdfe72362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4b436330-604f-4036-9df5-7ee1de7b472c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_TradingSymbol_4b436330-604f-4036-9df5-7ee1de7b472c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_3155bac9-a016-4ee1-aca1-465c53c3de76" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_NoTradingSymbolFlag_3155bac9-a016-4ee1-aca1-465c53c3de76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_204ef8ad-4cf4-4667-9e4e-9e7662b96f50" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_SecurityExchangeName_204ef8ad-4cf4-4667-9e4e-9e7662b96f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4143d10e-3011-42ff-a61a-799fb80a7bf8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityEmergingGrowthCompany_4143d10e-3011-42ff-a61a-799fb80a7bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_74fd64b1-9d66-4add-970b-8b26d907eec3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_EntityCentralIndexKey_74fd64b1-9d66-4add-970b-8b26d907eec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_74011290-b1b1-4761-894a-5559c1d9eb7f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_513afad6-c1b2-4026-9456-2576b84e8147" xlink:to="loc_dei_AmendmentFlag_74011290-b1b1-4761-894a-5559c1d9eb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>a1a.jpg
<TEXT>
begin 644 a1a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  9 &L# 2(  A$! Q$!_\0
M'0   @$% 0$             !@<  0,$!0@""?_$ #00  $$ 0($! 4"!04
M      $" P0%!@ 1!Q(Q41,A06$(%"(R@3-Q%192H<$C8I'A\/_$ !H!  (#
M 0$               0% 0(#!@?_Q  Q$0 ! @0$ P<"!P         ! A$
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MM)W"@=MB-#4N,*GIE)6FU:B 1T()!'3**IFNSC."_*L^QS"3!_C]U#J/GG?
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  06,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Dynavax Technologies Corporation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0728374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2100 Powell Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Emeryville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">848-5100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001029142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DVAX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dvax_PreferredSharePurchaseRightsMember', window );">Preferred Share Purchase Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Preferred Share Purchase Rights<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dvax_PreferredSharePurchaseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dvax_PreferredSharePurchaseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ': IEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ': IEI>'H,"[P   "L"   1
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
M6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<
M_N\-L,+$CN'MB[\!4$L#!!0    ( ': IEI=JK+YW 0  -<5   8    >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&ULM9AA<^(V$(;_BH9V.NU,$MLR 9(",P22
M*W.7' WTKM-./PA;@":VY4HRA'_?E2$VZ9DUR<Q] 1NLUX^UN^_*ZFZD>M(K
MS@UYCJ-$]QHK8])KQ]'!BL=,7\B4)_#/0JJ8&3A52T>GBK,P'Q1'#G7=EA,S
MD33ZW?RWB>IW968BD?")(CJ+8Z:V-SR2FU[#:[S\\"B6*V-_</K=E"WYE)L_
MTHF",Z=0"47,$RUD0A1?]!H#[_K&IW9 ?L47P3?ZX)C81YE+^61/QF&OX5HB
M'O' 6 D&7VL^Y%%DE8#CW[UHH[BG'7AX_*)^ES\\/,R<:3Z4T5<1FE6OT6F0
MD"]8%IE'N?F-[Q_HTNH%,M+Y)]GLKFTV&R3(M)'Q?C 0Q"+9?;/G_40<#/#]
M(P/H?D ^$<[N1CGEB!G6[RJY(<I>#6KV('_4?#3 B<1&96H4_"M@G.F/9)#!
M)!LR2$)RFQAAMF2<[*(-L]9U#-S$7NH$>\&;G2 ](GC/ML1MG1'JTLO7HQU
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ =H"F6I>*NQS     $P(   L
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M/UY_ 5!+ 0(4 Q0    ( ': IEI&QTU(E0   ,T    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ =H"F6EX>@P+O
M*P(  !$              ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ =H"F6IE<G",0!@  G"<  !,              ( !X0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " !V@*9:7:JR^=P$  #7%0  &
M            @($B"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ =H"F6I^@&_"Q @  X@P   T              ( !- T  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " !V@*9:EXJ[',     3 @  "P
M    @ $0$   7W)E;',O+G)E;'-02P$"% ,4    " !V@*9:.JJBYT !   \
M @  #P              @ 'Y$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ =H"F6B0>FZ*M    ^ $  !H              ( !9A(  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ =H"F6F60>9(9 0  SP,
M !,              ( !2Q,  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  E10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="dvax-20250506.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dynavax.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="dvax-20250506.htm">dvax-20250506.htm</File>
    <File>dvax-20250506.xsd</File>
    <File>dvax-20250506_def.xml</File>
    <File>dvax-20250506_lab.xml</File>
    <File>dvax-20250506_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dvax-20250506.htm": {
   "nsprefix": "dvax",
   "nsuri": "http://www.dynavax.com/20250506",
   "dts": {
    "inline": {
     "local": [
      "dvax-20250506.htm"
     ]
    },
    "schema": {
     "local": [
      "dvax-20250506.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "dvax-20250506_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "dvax-20250506_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dvax-20250506_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 1,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 31,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 26
   },
   "report": {
    "R1": {
     "role": "http://www.dynavax.com/role/DocumentAndEntityInformation",
     "longName": "0000001 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20250506.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dvax-20250506.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No Trading Symbol Flag",
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dvax_PreferredSharePurchaseRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.dynavax.com/20250506",
     "localname": "PreferredSharePurchaseRightsMember",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Share Purchase Rights",
        "label": "Preferred Share Purchase Rights [Member]",
        "documentation": "Preferred Share Purchase Rights"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.dynavax.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001029142-25-000069-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001029142-25-000069-xbrl.zip
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MKF6@ HL]^@?Y'$1]&H"_'(#'3,ZI^+Z:T/*::9-[$+-^G EV$<UEF5IK5D>
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M:$@%>[(@#TS3ATTL, @:HE %ROIL2 ,?0RXXD%*P60<,N[ $ SIJ/)K(820
M.Z]PH/CM[)NKSY0*7JF4C.IV>>B;AK)*S>;S;.854,^2G[YME9_73VO9A=%Z
M],AA79;;/=MC5A\XV=LI^5^T9--.V$7EO"3&\SE-CR29[]#,K)89WS+_;.]9
M^K>I0]Z3&UR.R^0+"\#JGE/W+ IIX*U5(GNE,/Y$GO1S1U!?M!#)/<84OY>S
M(WA[+.21(/_D+F[Q6:Q^R]D1:7^ZW#J_<4\V2N7TUTFJWT'9^G]02P,$%
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MX, 7N.J2IU6U]!A9/F+A&'<'YF>)[=O%:1DSQXO@?SJX.$O+F>!5P,4FL#9
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MR"H82I>2HN+K!.[! 0C:FA$/.J:]@ H& R$*NJ2"&C@7N:WT:56[B&;;45!
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MCNHQ@JVH-<5N-6B(%T.W^5@ZX557'1&@DYD*C5^UQE8$H,L!9FM3SD0.9&,
MN<I60F"4#3;-/"7U-*4;G-E$V4]:]!\:)/5?YC=VX2.SP49"@^/)G3) 5?R"
M&IU\>1*I*,43?CQ7Y)8D 68L4*D[4F+% $2QA=2A06+L"V['1P&=YU*U<?W^
ME<09?*'@ D2H']$B8M0J_TH.*O5F%(F/8?:TBD1U=63%1 F]@OHLSXE@(L2+
M"'?EQB^C$51GW;0I(DU)GR'%U".<6HN46N"(*CWB:_7JI'L2Q2-G1"P^*1&S
MIVB9I$$HK62YT".92#-B28=AT2%0\EK\'MB:*T2=V H'.5P$.B+0*0D_!P5D
M3%$QV.52/3W7!8J">2+VC1"YYO==V6E0>,#O'*%AQ1-Z>S8Z"4?B>%E'N4C:
M)FW("8")8ZTXBX>SGB].J:X#D"#WN0?V,5 5%TTE*U1SX=R^MSCG?R:D3F5R
MH-833'Q1':P_%65&*%K%R1=:2@A)1KVDNWES?EI<ZX>:3;H-&*Z,;;]0;5P<
M/0P_6<1,88NP8Y@#]R.A!$AH'J.8"_P962I&$'@QDCUL6D"W$-'?.ZB')QH<
M1N]$3A1'1"9"022>ZMEP7&0%[B2O7IH!T,3/[GPRV$J41B?G5PRP\M(DT!%&
M"DNUFB(-1*LV4FM(112Z/Q5NRKP0JX!C#[4"V*X6Q\MC<&FFLH79/OG$;8=M
MTFSQF76;SRQV@8'-!_<_[S FEO_]A]<M\R1SX'<\I"8(L%:K6:F9W>[.R6WQ
M$*\<> .H>8%G1SM>+1!$,(B";F&[WC(+;F?"1SOV+Z\<PVYUK&Z_;S98VS3-
M?I^99MML&=T6;[*&7?^O^>K%V*9:RCLE'H4='7CPY,W6%[/VL_]<]7[O_5N[
M/3_][>KZ\OK7B_,;[?3ZR^?K+ZO+7A1E J?75S?7EQ=GO=OS,^WF%O[Z='YU
M>Z-=?]2N/Y^+22QOE5F461Q1XU8_AF?8I!-CS]1,1P3AR0C?%7\B7SVLL84M
M&]:5+@O/@JR\KKA2 *"_ G-PV23DQ^J'$]"3L/35L>/12.BF!YU=+',K.$8$
M["RRU9OEUU7ZZJ?(GO^N7:]V&MVE7]>JQM+O5CW6,*JM>OM!CUW]G5EK/<U@
M.VL]]B=:7['&L(WAA'F_O&HD/!B;$0\#]&E6),4.Z!_ETSZN:0;A$?6BY!G=
M]9]1GWS'I\S3W2RA"!IY_I-4$^9YM"U\$K:%\[PE,#E:3[JD:SQ#GDP\RC6,
MNM H-4)3J[/QBH\=VW;Y\Z^X8<**HZTFM[)/LQCE>J?K;3Z.DBV+\]4'&V-@
M=C3I>4N(2980T6,ZKSQO0@IRTAE2J%?K&]'"HD5Y)EZW>%&$O53\^9@U>=01
M>TGK^EB9(2>OX=^=:J-=\$/W.5\M7<<XDUDZVV3J-6T?=O_-HZ:8G1I562G4
MW%JFWFUV%W.,AQ#Q!M-]B-Q>QIA*HMLGHC/;>L=L[H[HMH2/]H5K7PLO;K[#
MQ=SIJV\V_X6GJ'BDUM#KM4TI;<5N/Q5[6Q=W'>8FU?7NQNQ@BYNT)1!7$!ZP
M6$>\]2,*[!%*TX.8P.:J<^'(;_':M#JZD7J =J=?;"H*-S-B[!*>O6SZ:M;T
M=K=6TM?3(;&"L-XE\&LN=6^;-JL-S9>%TW,*:K(ZV&5]81:K4YDU&3(7'EI1
M86./ 4"%ED"+5\%HZ.W6_EMY#GV7:GJWU2K-(L_F00HY.8)GBG>^, N)T=4;
M[79I(BGX+C7T9KVS]S:2?>$--]QU*>=()AF*-/A,$Y>[AQE2]U<XF6V]U=Z4
M $L(\=R[9.JU5G$]*RK.T/.Q)>NJC7VN*P]MP(<&TCXP6U6M(=O)2P-GH!*T
M:R4X*_8N46&8^A(CUAZALX)P@E4>K/DZ:*4O*[M*74-O=TM?5D$0Y.'15ZNC
M-YO=DKX*X,O:)%]RJSMPB=4$9SIGS*0NO@RY?U1OZ*U&[5V)S J[0T8;/1\[
MV:'# F6K0@MEI<$C"<G>/=R__; E**:G=0=I9 >Q;B_,PG&1;W_SP@P<P)X;
MFSJF2RGZS)O4U<U6Z7MZ=H;P&)/G_KHPC@R]U:VOC]A*'],N-JBYDPUZ8=#@
M)NZ+.IJS %L[NO(CKLUOPH$+HKI>KV\:(%6BA1WPA]H&#+Q$"H\RQ"UNZ_'2
M0$.GKM=V))1*U/!T/M(2.SS.,G>$G7_>O4S3PI%9;Y2F^<)NCU$S]MZD4'Q?
MW16/1/>OOFCVG&V2] B?W0'XMY<PC6Y;[[0W!Q)E_,*>[*]AZ&:W7<3]?3'Q
M Q^RG7NWQ)#V6 [J[79ITRCX)M5WNTD'"%<6AY<IN+*8$SRUN-JACWSQ<FQ<
M!&R3%2C*B5L\]:-N2Z]U-XC<V3L@5E+S"Z+FCMZN&T4DY@-$G:M%2[8;0!0%
M3C^.5$=>[%9$C>!]Z]O(=V'I_PF2;E94I#'!'KCHU#NLFB*[+=5RJ*MZL,ZL
MQ>?S PL=ZY"*"6])".Z3E*M5VYN;5O8(DI7D5J2Y ;G5=D-N!^M+7+S09PYV
M+K,WM7RL+Z,/[2QMO@"%/VF;,/:'8+1=&B]+0GY!A+R)R'@V0GXQ!MX_Z!=N
M5Q@,C0VYT,1#T>;7\:A!>DSY_=Z#]/4%O70? A!?@'JY@_2T%["J+PP9+E3:
M#\87N'C.1MW4.VUCCVH@E.[BYR:11DVOU_:IY'OQG-7[P@*7*,</"+.2G787
MB,9'*B %/"![QT.WOU7[%P?XD@AT[SAX<0B4!,!/I*6]G^]:+N=H8D/QB1\Z
M6#[H.. N%=5-^XB_?96[2\ZGEM["^J&/G'?N%K%;[W_NXRARBF#F3WRT8__R
MRC'L5L?J]OMF@[5-T^SWF6FVS9;1;?$F:]CU_[9?J7M&@1K-!#372C_@[%N%
M#2(>'#/WGDW#_)#'CE?)3G9^G,YXJ#$W^N45,UCUS\D0#F)@97_+K5C#G'Q_
M4%-VLS7Y_FI^^FJ8:1?Y5OY4)DWDG_D UG&%SOYSU?N]]V_M]OSTMZOKR^M?
M+\YOM-/K+Y^OO_1N+ZZOM/S>9B94E!G<G%^>G]Z>GVD?>I>]J]-S[>:W\_-;
M[:QWVRO\V(\N/"T:^3$\PP[?%7^X7ST6VP[ L.5CS=!YW21)*.Q("8,AM@@C
M=MDDY,?JAQ-5A-?QZ+UTTX..8:U6K8G#+\&Q?+/\NDI?S;!Y\5VK6>VTNDN_
MKE6-I=^M>JS1K!I&_4&/7?V=66L]S6 ;:SWV'Q20#2Q9*TQ2!>P#_XFZ630,
M'45?O59OKF'ORRT&@+-&M=T^K%4YXQ8?]WF061CSR4QV8OD*K:_VPI!'RZOF
M;A9[92R-252DI&TIRBOSID6*S9JD^Q1SVJ:]HU#TLZ2C%@M'NF;!GQK_*W;N
MF MG/J0&&2 5OW$I5;D5!P#4Y^LS/TF,S4Y79,Z=NHEJG9VNI*[U=*Z=3KG5
M,O1&H[4UA]*BXUL2R@$02MMHZ)W&"Q&XR^JYW0&'](-->.&ZKH]G=(S6_FFR
MI-ML'%I2B."1]>;6-G6SUMA/W]M&#+:DOB)27TVO-<W#<.OM =<6]7, Q ;
MO#6V4&G:IW#Q;1^@(H6+KS>W3DVO-S:M.5/F*)1$]YBYM9K M3?%# 7-5"@4
MUU[5).J!7/N?3$&%UCC7C/3>)/!JO84HHBZZ>#$Z1A.[Z6TG=76)=;,DKI=*
M7&9'[YK&XPP=^PV9!?/U?*]2PN;#03!&O:MWF_O?^;FDNKVBND9;;QC%[61]
MF,"Y!,PEILDL1M<$P%SO;*W6RT.,T"5Q'2IQ=5IZO=E:!)AG E^-I@C7V[)_
M>9.'K1<T_92O*MJL7IA\O'18WW$IH(5"7?(YQYVZT3ZA<)AH^J3<LJ />Y&*
MKE)RW90T2DUWGW6.5D=OM#=M1EDJNB71/<JMW]%;C4W=^J6>^SC6[?K>L!+Q
M8/P@YEV&QQ3P'#7,EMZJ[;!+[3/5HBJIKDAS:Q@UO5/?84S@"T/>-VNK724*
MVJ=SU&S4T'M:8N^2ZIZ3ZKHMO=W=H<9WL.![E9/)?; I;4T3^5JU+TIGPA96
M:H^\#8]W92U?LW5M\R7]EO2[;6_9TCH[\_4NQ*US97'VN#:/42N+\SPS-1Y(
M<9XOYZ?75Z<7EQ=BO-<?M5][O<_:U?FM=GE]<Z/=7FN]L__S]0;K]YQ_N+@]
M*VOV[*!FS[*QKN9BB^YZWEH_W6ZUU6T]I-1/VZAVS,[VJ^?4JT;]H>5\5I?Z
M:3_-8,UU'[L PJEM]'R/%^/*QY8DZNYI\9W;4<"Y]@FN&X7:N6>OJ)-Z $N]
MJXJ5A%K2ZD]%7^%'5)+:Z0H_I*36@<W??'+BV@'!;JO'9;(YN^BN03M$&-9[
M6 _E OH7UYOT?OH7UYO;QEV02X=V27"/(K@-&Q4_.;T=@#19[# J"(DO]HSU
M[#_C,!IC9;]\1Z4M^DH+_(P#(+H5!]-8KZM&Y$]V%.5QQB<!MQR&MF3MA]>-
MSHG&QCX,[F_ZZ&#[#2V),6KOL.K3ED# P6_1IIFJI=Q\5*A:X5G8!6KO/(PT
MQ[/\,=]6X<\].0]';;W=V$!K*5X@UZ%O4%<W6YT";= !L*M]1EP)N^+?)]P+
M'\:O]E=^&WJK6R^:!"]!UOPFE3"K*.8)P:LR7G=Y?P4O/C;:Q/!VQ,T^<(\/
MG$@;!/Y8 C M8M_Y$I/XH<MZ0V^W6P62]248F]F@>L$VZ "8VL,\> 6(CF>I
MY?7IJ\44[H L<4JT==/<W FVWAKL$6@[K$TU:KK1-O=B5P^ (3X,Y>V4(<[$
MW3X #!S:@6GH37-SJTTQ^. 6,=Z!;6M'[W2;>[&K!\ ']]E*1]GOE3X+.4YV
MC):ZE^@0-1H(!XMF"2K-=;-UHW7#+)SG^@ XV#Z[12_],-1\3[-Y'WT-$4P@
M=L(1JKLOS$7:J>NUC<W9I6GNF7>)ZA'43XJV30? Q?89AWT._.]3F*87H<O4
M\L,HU%X8!FOH+7/_BZT=^"8]C'N5&.P@K6DBI!LTQ\5FM37-#8LK;FR[,,F>
MI'=L<VF*PDF6&*E,O='<W$6YC979,< MST5Y+E:<BY;>;FZ0+E78<U%0F;RT
MNE$Q*A7]U/?M*?PUBL;N^_\/4$L! A0#%     @ =H"F6EV#$&I]$   %W8
M !$              ( !     &1V87@M,C R-3 U,#8N:'1M4$L! A0#%
M  @ =H"F6B^@YN4Q P  D0H  !$              ( !K!   &1V87@M,C R
M-3 U,#8N>'-D4$L! A0#%     @ =H"F6LY_=]&_"   AT   !4
M     ( !#!0  &1V87@M,C R-3 U,#9?9&5F+GAM;%!+ 0(4 Q0    ( ':
MIEIR6AS0+PT  "!S   5              "  ?X<  !D=F%X+3(P,C4P-3 V
M7VQA8BYX;6Q02P$"% ,4    " !V@*9:M4F.VG$(  "E0P  %0
M    @ %@*@  9'9A>"TR,#(U,#4P-E]P<F4N>&UL4$L! A0#%     @ =H"F
M6B=P5#5O+P  O\T! !X              ( !!#,  &1V87@M97AX.3DQ>&5A
F<FYI;F=S<')E<W-R+FAT;5!+!08     !@ & ),!  "O8@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>dvax-20250506_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:dvax="http://www.dynavax.com/20250506"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dvax-20250506.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
        </entity>
        <period>
            <startDate>2025-05-06</startDate>
            <endDate>2025-05-06</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-06</startDate>
            <endDate>2025-05-06</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001029142</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dvax:PreferredSharePurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-06</startDate>
            <endDate>2025-05-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001029142</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-05-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Dynavax Technologies Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-34207</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">33-0728374</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">2100 Powell Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 720</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Emeryville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">94608</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">848-5100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-18">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-19">DVAX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-21">Preferred Share Purchase Rights</dei:Security12bTitle>
    <dei:NoTradingSymbolFlag contextRef="c-3" id="f-22">true</dei:NoTradingSymbolFlag>
    <dei:SecurityExchangeName contextRef="c-3" id="f-23">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-24">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
